Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
9.67
-0.20 (-2.03%)
At close: Sep 13, 2024, 4:00 PM
10.62
+0.95 (9.82%)
After-hours: Sep 13, 2024, 4:04 PM EDT
Lexeo Therapeutics Employees
Lexeo Therapeutics had 58 employees as of December 31, 2023. The number of employees increased by 34 or 141.67% compared to the previous year.
Employees
58
Change
34
Growth
141.67%
Revenue / Employee
n/a
Profits / Employee
-$1,331,293
Market Cap
319.70M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Treace Medical Concepts | 516 |
| MeiraGTx Holdings | 425 |
| Pulmonx | 279 |
| Editas Medicine | 265 |
| Personalis | 225 |
| Lyell Immunopharma | 224 |
| AC Immune | 161 |
| Atea Pharmaceuticals | 75 |
LXEO News
- 8 days ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 2 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha
- 2 months ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga
- 2 months ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 5 months ago - Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy - GlobeNewsWire